Navigation Links
Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Date:12/10/2007

THE WOODLANDS, Texas, Dec. 10 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a member of Lexicon senior management will participate in the RBC Capital Markets Healthcare Conference panel Going With Your Gut: New Treatments for GI Disorders at The Westin Times Square Hotel in New York, New York on Wednesday, December 12, 2007 at 8:00 a.m. Eastern Time.

A live audio webcast of the panel presentation may be accessed on Lexicon's corporate website at http://www.lexpharma.com. An archived version of the webcast will be available on the website through December 20, 2007.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, and rheumatoid arthritis. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This p
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... second contract from the U.S. Environmental Protection Agency ... company’s expertise in developmental toxicity models, including tests ... on neuron formation and the formation of connections ... function. Inhibition of neurodifferentiation and synapse formation by ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
(Date:7/29/2014)... 2014   Sequenom, Inc. (NASDAQ: ... genetic analysis solutions, and Mayo Medical Laboratories (MML), ... the United States , have announced ... applications. "We have great appreciation for Mayo ... we welcome the opportunity to partner with the organization,s ...
(Date:7/29/2014)... has created a new way of manufacturing microstructured ... made by self-assembly of carbon nanotubes, could exhibit ... mechanical stiffness and strength, or the ability to ... have demonstrated that mechanical forces can be used ... and that we can independently control the ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4A new way to make microstructured surfaces 2
... Neb., March 18 Transgenomic Inc. (OTC Bulletin Board: TBIO) announces the following Webcast: , , ... Conference ... 5:00 p.m. Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , ... on to the web at the, ...
... Pharmaceutical Inc. (Nasdaq: BMRN ) announced today ... BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the ... (MPS IVA), or Morquio A Syndrome, has been accepted ... Agency (MHRA). BioMarin expects to initiate a Phase 1/2 ...
... BALTIMORE, March 18 Champions Biotechnology, Inc. (OTC Bulletin ... advanced preclinical platforms and tumor specific data to enhance ... for the third fiscal quarter ended January 31, 2009. ... available in the Company,s Form 10-Q at www.championsbiotechnology.com ...
Cached Biology Technology:Reminder - Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 6
(Date:7/30/2014)... a paper published online today in the journal ... researchers Evan Kodra and Auroop Ganguly found that while ... variability in temperature extremes. For instance, while each year,s ... averages will also tend to fall within a wider ... are currently being observed. This means that even as ...
(Date:7/29/2014)... climate warms and sea ice retreats, the North is ... increasingly open water which is predicted to extend across ... century. Storms thus have the potential to create Arctic ... and unpredictable element to the region. , A University of ... the middle of the Arctic Ocean, and detected house-sized ...
(Date:7/29/2014)... July 29, 2014 Research and Markets ... Business Intelligence (BI) Market 2014-2018" report to their ... The term BI refers to applications and ... or analyzing information about a company,s operations. BI help ... their business; for example, metrics on sales, production, and ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3Global SaaS-based Business Intelligence (BI) Market 2014-2018 2
... than their unaffected siblings to have higher levels of ... The hormone, leptin, may contribute to the known higher ... syndrome. A research team from The Childrens Hospital ... Medicine published their study online today in the Journal ...
... October 26, 2007 A new study ... predators and parasites, for mixed mating, a reproductive ... through both self- and cross-fertilization. The findings highlight ... Mating systems are a complex set of traits ...
... Hurricane Katrina on soil quality and agriculture? How can soil ... can biofuels help make America energy independent? These topics and ... Annual Meetings of the American Society of Agronomy (ASA), Crop ... America (SSSA) Nov. 4-8, 2007 at the Ernest N. Morial ...
Cached Biology News:Obesity-related hormone is higher in children with Down syndrome 2Predators and parasites may increase evolutionary stability 2Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings 2
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
Monocarboxylate (lactate) transporter 2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: